Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo*, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E. Lonning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csoszi, Roberto Bordonaro, Thomas Decker, Vivianne C. G. Tjan-Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila SellamiThomas Bachelot

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

186 Citations (Web of Science)
Original languageEnglish
Pages (from-to)87-100
Number of pages14
JournalLancet oncology
Volume19
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • ENDOCRINE THERAPY
  • AKT
  • COMBINATION
  • RESISTANCE
  • PATHWAY
  • ACTIVATION
  • EVEROLIMUS
  • MUTATIONS
  • BKM120
  • TUMORS

Cite this